Shares of Replimune Group Inc (REPL) closed 38% lower on Tuesday, clocking its worst day since early April, after the U.S.

Iovance Biotherapeutics reported strong Q2 results, with revenue reaching $99.3 million on rising Amtagvi demand. ・FDA granted Replimune accelerated approval for TUDRIQEV (RP1) combined with nivolumab ...

No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...